2/5
09:54 am
oncy
$207B Market Shift: The Race for Fast Track Approval in Oncology [Globe and Mail, The (Toronto, Canada)]
Low
Report
$207B Market Shift: The Race for Fast Track Approval in Oncology [Globe and Mail, The (Toronto, Canada)]
2/5
09:26 am
oncy
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
Medium
Report
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
2/4
08:50 am
oncy
Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer
High
Report
Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer
1/30
10:50 am
oncy
$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium [Globe and Mail, The (Toronto, Canada)]
Low
Report
$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium [Globe and Mail, The (Toronto, Canada)]
1/30
10:33 am
oncy
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors [Globe and Mail, The (Toronto, Canada)]
Low
Report
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors [Globe and Mail, The (Toronto, Canada)]
1/30
10:19 am
oncy
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors
Low
Report
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors
1/28
09:45 am
oncy
Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment [Globe and Mail, The (Toronto, Canada)]
Low
Report
Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment [Globe and Mail, The (Toronto, Canada)]
1/27
11:11 am
oncy
Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks [Globe and Mail, The (Toronto, Canada)]
Medium
Report
Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks [Globe and Mail, The (Toronto, Canada)]
1/27
10:50 am
oncy
Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks
Medium
Report
Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks
1/26
10:13 am
oncy
THE RESILIENCE DOCTRINE: 5 Assets Securing the 2026 Sovereign Stack
Medium
Report
THE RESILIENCE DOCTRINE: 5 Assets Securing the 2026 Sovereign Stack
1/15
04:17 pm
oncy
Oncolytics Biotech® Announces Results of Special Meeting of Shareholders [Yahoo! Finance]
Medium
Report
Oncolytics Biotech® Announces Results of Special Meeting of Shareholders [Yahoo! Finance]
1/15
04:01 pm
oncy
Oncolytics Biotech® Announces Results of Special Meeting of Shareholders
Medium
Report
Oncolytics Biotech® Announces Results of Special Meeting of Shareholders
1/14
10:39 am
oncy
The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era
Medium
Report
The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era
1/14
10:15 am
oncy
THE SOVEREIGN MANDATE: 5 Stocks Securing the 2026 Choke Points
Medium
Report
THE SOVEREIGN MANDATE: 5 Stocks Securing the 2026 Choke Points
1/14
09:00 am
oncy
Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics
Medium
Report
Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics
1/12
11:24 am
oncy
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 [Globe and Mail, The (Toronto, Canada)]
Medium
Report
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 [Globe and Mail, The (Toronto, Canada)]
1/12
10:14 am
oncy
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
Low
Report
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
1/12
09:00 am
oncy
Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer
Low
Report
Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer
1/12
04:40 am
oncy
Oncolytics Biotech (ONCY) Leadership Strengthens As Pelareorep Advances [Yahoo! Finance]
Low
Report
Oncolytics Biotech (ONCY) Leadership Strengthens As Pelareorep Advances [Yahoo! Finance]
1/10
09:18 am
oncy
Oncolytics outlines strategic rationale for proposal to change jurisdiction [Yahoo! Finance]
Medium
Report
Oncolytics outlines strategic rationale for proposal to change jurisdiction [Yahoo! Finance]
1/9
09:47 am
oncy
Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada [Yahoo! Finance]
Medium
Report
Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada [Yahoo! Finance]
1/9
09:00 am
oncy
Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada
Low
Report
Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada
1/8
01:28 pm
oncy
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech [Canadian Business Journal (Canada)]
Low
Report
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech [Canadian Business Journal (Canada)]
1/8
12:08 pm
oncy
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech
Medium
Report
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech
1/8
09:00 am
oncy
Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings
Medium
Report
Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings